Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare

Diabetic Macular Edema (DME) Filing Possible In 2021

New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Forecasts for Beovu have been downgraded after the safety concerns emerged in February

Novartis AG’s Beovu has matched market-leading ophthalmic therapy Eylea in a new Phase III study, part of its efforts to establish the new less frequently dosed therapy.

The topline results from a Phase III non-inferiority study should pave the way for Beovu (brolucizumab) to add diabetic macular...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.